SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in several medical events throughout March 2022. Key highlights include a live panel discussion on drug development in Women’s Health, led by CEO Marco Taglietti. The company will attend three in-person conferences: ISSWSH from March 3-6 in Dallas, CREOG & APGO Annual Meeting from March 9-12 in Orlando, and AMCP from March 29-April 1 in Chicago. Additionally, SCYNEXIS will participate in a virtual investor panel at Maxim Group’s Annual Growth Conference on March 28.

For more details, visit www.scynexis.com.

JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conferences and one virtual investor panel in March. Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a live panel discussion on drug development in Women’s Health. Event details can be found below:

Conferences:

• International Society for the Study of Women’s Sexual Health (ISSWSH)
  Date: March 3-6, 2022
  Location: Dallas        
  Event Page

• Council on Resident Education in Obstetrics and Gynecology (CREOG) & Association of Professors of Gynecology and Obstetrics (APGO) Annual Meeting
  Date: March 9-12, 2022
  Location: Orlando
  Event Page

• Academy of Managed Care Pharmacy (AMCP)
  Date: March 29- April 1, 2022
  Location: Chicago
  Event Page

Virtual Investor Panel:

• Maxim Group’s Annual Growth Conference
  Panel: Women’s Health Virtual Event
  Date: March 28, 2022
  Location: Virtual
  Time: 3:00 p.m. ET
  Event Page

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, late-stage clinical investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com. 

CONTACT: 
Investor Relations
Irina Koffler
Managing Director
LifeSci Advisors, LLC
646-970-4681 
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
646-970-4688
ggasaatura@lifescicomms.com

FAQ

What events will SCYNEXIS participate in March 2022?

SCYNEXIS will attend the ISSWSH Conference from March 3-6, CREOG & APGO Annual Meeting from March 9-12, AMCP from March 29-April 1, and a virtual panel at Maxim Group’s Annual Growth Conference on March 28.

Who is representing SCYNEXIS at the medical conferences?

Marco Taglietti, M.D., President and CEO of SCYNEXIS, will participate in a live panel discussion at the events.

What is the focus of the live panel discussion involving SCYNEXIS?

The live panel discussion will focus on drug development in Women’s Health.

What is the significance of ibrexafungerp for SCYNEXIS?

Ibrexafungerp, the lead asset of SCYNEXIS, is being developed as a broad-spectrum antifungal to treat drug-resistant infections.

When was BREXAFEMME approved by the FDA?

BREXAFEMME was approved by the FDA on June 1, 2021.